A Phase 4 interventional study of Paliperdidone ER and Aripiprazole, olanzapine and risperidone (Antipsychotics) in Schizophrenia, sponsored by Janssen Korea, Ltd., Korea. Terminated at 9 sites in Korea, Republic of. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-25.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 652 studies testing antipsychotics in Schizophrenia — 23 open to participants now, 24 under way, 6 of them phase 3. A drug class: Antipsychotics · Schizophrenia.
Among the 652 studies testing antipsychotics in Schizophrenia, this one is the 601st largest by enrollment of the 644 interventional ones that give a count, is one of 32 that started in 2012, is one of 247 in phase 4, and was the 425th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →23 of the 652 studies testing antipsychotics in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Vanda Pharmaceuticals · Sites in United States
Ages 18–65
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–65
Northwell Health · Sites in United States, Canada
Ages 18–35
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
652 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 54 · Phase 3 233 · Phase 4 247
First in 1994; this study’s year is marked. 32 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 111 across the 644 interventional studies. Of the 571 that completed or were terminated, 236 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
410 of 652 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Korea, Ltd., Korea, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 167th largest by enrollment of the 176 interventional ones that give a count, is one of 7 that started in 2012, is one of 47 in phase 4, and was the 158th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
12 of the studies testing antipsychotics in Schizophrenia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT06961968Phase 3Vanda PharmaceuticalsRandomized Withdrawal Study in Patients With Schizophrenia | 2027-11 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 652 studies testing antipsychotics in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the patient satisfaction between continued administration of previous antipsychotics versus switched administration to paliperidone ER in non-satisfied patients with previous (paliperidone)
This is a randomized (patients are assigned to intervention by chance), prospective, open-label (all people involved know the identity of the assigned drug), switch study designed to evaluate patient-assessed medication satisfaction after 12 weeks of treatment in patients with schizophrenia. The total duration of this study is 12 weeks. Outpatients who treated atypical antipsychotics and report dissatisfaction (Medication Satisfaction Questionnaire [MSQ] \<4) with their current treatment response are eligible to participate in the study. Patients will be randomized into two groups, 1) Patients randomized to an immediate initiation of paliperidone ER for a total 12 weeks 2) Patients randomized to a delayed initiation will continue their previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. During the study treatment optimization will be done by dose adjustment (dose increase or decrease) and by adding psychotropic agents except the antipsychotics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immediate initiation of Paliperidone ER for a total of 12 weeks
Drug: Paliperdidone ER
Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
Drug: Paliperdidone ER · Drug: Aripiprazole, olanzapine and risperidone (Antipsychotics)
Form = osmotic release oral system, route = oral
Drug page: Antipsychotics
Form = tablet, route = oral
Change From Baseline in the medication satisfaction questionnaire (MSQ) score at Week 8
A single-item, global, patient-completed instrument that is read aloud to patients by clinicians designed to assess treatment satisfaction among patients with schizophrenia. It consists of one question: "Overall, how satisfied are you with your current antipsychotic medication(s)?" with responses assessed on a 7-point scale rated as follows: 1 = extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6 = very satisfied, 7 = extremely satisfied
Time frame: Baseline and Week 8
Positive and negative symptoms scale (PANSS) score
The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme). It's designed to capture symptoms of schizophrenia. (Gold standard)
Time frame: Baseline to Week 12
Drug Attitude Inventory (DAI)-10 Score
DAI-10 is a 10-item scale developed to assess how the attitude of schizophrenia patients toward their medications may affect compliance (-10\~+10)
Time frame: Baseline to Week 12
Clinical Global Impression-Severity (CGI-S) Score
The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe)
Time frame: Baseline to Week 12
Personal and Social Performance Scale (PSP)
This scale assesses the degree of dysfunction a patient exhibits within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Patient's with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; ≤ 30, functioning so poorly as to require intensive supervision
Time frame: Baseline to Week 12
Sleep Visual Analog Scale (Sleep VAS)
This self-administered scale rates quality of sleep and daytime drowsiness. Patient's will indicate on an 11- point scale (from 0 to 10) how well they have slept in the previous 7 days ("very badly" to "very well") and how often they have felt drowsy within the previous 7 days ("not at all" to "all the time"). On the sleep evaluation scale, score '0' corresponds to 'very badly' and score '10' to 'very well'. On the daytime drowsiness scale, score '0' corresponds to 'not at all' and score '10' to 'all the time
Time frame: Baseline to Week 12
Number of patients with adverse events
Time frame: Baseline to Week 12
Number of patients with vital signs and physical examination
Time frame: Baseline to Week 12
Number of patients with laboratory test (prolactin, blood glucose, glycosylated hemoglobin, cholesterol, triglyceride)
Time frame: Baseline to Week 12
The record gives a start of Jul 2012, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Antipsychotics